StoxCohance Lifesciences vs Concord Biotech: share price & financials comparison
NSE: COHANCE vs CONCORDBIO · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Cohance Lifesciences vs Concord Biotech at a glance
Cohance Lifesciences (COHANCE) has a market capitalisation of ₹17,546 Cr, against ₹6,214 Cr for Concord Biotech (CONCORDBIO). Over the past year Concord Biotech has returned -18.3%, compared with -38.3% for Cohance Lifesciences. On valuation, Concord Biotech trades at a lower P/E of 22.0 versus 370.4. Concord Biotech earns a higher return on equity (13.6% vs 1.2%). Cohance Lifesciences comes out ahead on technicals. Concord Biotech comes out ahead on size, valuation, profitability, growth and momentum. Across the scored metrics below, Cohance Lifesciences leads on 3 and Concord Biotech on 11. On StoxGud's 10-point checklist, Cohance Lifesciences scores 5/10 and Concord Biotech scores 6/10.
| Metric | Cohance Lifesciences | Concord Biotech |
|---|---|---|
| Size | ||
| Market cap | ₹17,546 Cr | ₹6,214 Cr |
| Revenue (latest FY) | ₹2,269 Cr | ₹1,055 Cr |
| Net profit (latest FY) | ₹179 Cr | ₹261 Cr |
| Valuation | ||
| P/E | 370.4 | 22.0 |
| P/B | 4.48 | 2.99 |
| Dividend yield | — | 1.80% |
| Profitability | ||
| Return on equity | 1.2% | 13.6% |
| Net profit margin | 2.3% | 24.1% |
| Operating margin | 11.2% | 34.5% |
| Growth | ||
| Revenue growth (YoY) | -14.2% | +25.1% |
| Net profit growth (YoY) | -79.5% | +11.1% |
| Revenue CAGR (multi-year) | +18.2% | +1.8% |
| Financial health | ||
| Debt to equity | 0.06 | 0.00 |
| Momentum | ||
| 1-month return | +4.9% | -13.3% |
| 1-year return | -38.3% | -18.3% |
| 3-year CAGR | -7.4% | -3.0% |
| 5-year CAGR | -2.3% | — |
| Distance from 52W high | -36.6% | -25.2% |
| Technicals | ||
| RSI (14) | 53 | 47 |
| Price vs 200-day avg | +11.8% | -6.0% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Cohance Lifesciences | Concord Biotech |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 5/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Cohance Lifesciences or Concord Biotech?
Cohance Lifesciences has a market cap of ₹17,546 Cr and Concord Biotech has a market cap of ₹6,214 Cr as of 13 Nov 2026.
Which has a lower P/E, Cohance Lifesciences or Concord Biotech?
Concord Biotech has the lower P/E: Cohance Lifesciences trades at 370.4 and Concord Biotech at 22.0.
Which gave better returns in the last year, Cohance Lifesciences or Concord Biotech?
Concord Biotech did better: Cohance Lifesciences returned -38.3% and Concord Biotech returned -18.3% over one year.
What is the difference between Cohance Lifesciences and Concord Biotech?
Both are NSE-listed companies in Healthcare. Cohance Lifesciences is about 2.8 times the size of Concord Biotech by market cap. In the latest financial year Cohance Lifesciences reported revenue of ₹2,269 Cr and Concord Biotech ₹1,055 Cr. Operating margin is 11.2% for Cohance Lifesciences and 34.5% for Concord Biotech. Debt to equity is 0.06 for Cohance Lifesciences and 0.00 for Concord Biotech.
Which is better, Cohance Lifesciences or Concord Biotech?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Cohance Lifesciences leads on 3 and Concord Biotech on 11. Cohance Lifesciences is ahead on technicals. Concord Biotech is ahead on size, valuation, profitability, growth and momentum. On StoxGud's rules-based checklist Cohance Lifesciences scores 5/10 and Concord Biotech scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.